Altimmune (ALT) The Citizens Life Sciences Conference 2026 summary

Key clinical developments and trial results

• Lead molecule pemvidutide targets multiple liver indications, with MASH as the primary focus; phase II trials showed strong MASH resolution and tolerability, though fibrosis endpoint was not met due to high placebo response.

• 48-week phase II data showed continued weight loss and improved non-invasive anti-fibrotic markers, supporting a longer treatment window for efficacy.

• Phase III trial is set to begin in 2026, featuring a 52-week biopsy endpoint, two active doses (1.8 mg and 2.4 mg), and a titration scheme to further improve tolerability.

• FDA granted Breakthrough Therapy designation and approved use of AIM-MASH AI Assist tool to reduce biopsy variability.

• Additional phase II studies are ongoing in alcohol use disorder (AUD) and alcohol-related liver disease (ALD), with top-line AUD data expected in Q3 this year.

Differentiation, mechanism, and market positioning

• Pemvidutide’s one-to-one glucagon to GLP-1 ratio is unique, aiming for balanced efficacy and improved tolerability compared to other GLP-1/glucagon combos.

• Tolerability profile is considered best-in-class for incretins, with fewer titration steps and lower dropout rates than competitors.

• Preserves lean muscle mass during weight loss, addressing a key concern for MASH and MASLD patients and resonating with endocrinologists.

• Product profile is designed to be highly competitive on efficacy, early MASH resolution, and major fat reductions, with anticipated strong performance in phase III.

• Potential for use in combination with other therapies due to favorable tolerability and lack of drug-drug interactions.

Commercial strategy and market outlook

• Commercial planning is underway, with feedback indicating strong resonance of the target profile among physicians, patients, and payers.

• Market research highlights unmet needs in tolerability and efficacy for current GLP-1 therapies, positioning pemvidutide as a first-line option for F2/F3 MASH patients.

• The MASH market is expected to evolve with multiple mechanisms and patient segments, allowing room for differentiated products.

• Early success of Rezdiffra demonstrates growing physician and payer interest, but lack of weight loss in some competitors is seen as a disadvantage.

• Ex-US partnering remains an open option as part of the broader strategy to maximize patient access and shareholder value.